Ubiquitin-conjugating enzyme 2C promotes malignant progression of malignant rhabdoid tumor of the kidney via the Wnt/β-catenin signaling pathway

Tan Xiaojun; Zhou Yu; Zhao Pan; Li Yunxiang; Wu Ji; Liu Chuan

doi:10.13406/j.cnki.cyxb.003306

您当前的位置：

首页 >

文章列表页 >

Ubiquitin-conjugating enzyme 2C promotes malignant progression of malignant rhabdoid tumor of the kidney via the Wnt/β-catenin signaling pathway

Other tumors of urinary system | 更新时间：2025-10-21

- Ubiquitin-conjugating enzyme 2C promotes malignant progression of malignant rhabdoid tumor of the kidney via the Wnt/β-catenin signaling pathway
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 958-964(2023)
- 作者机构：
  
  1.南充市中心医院/川北医学院第二临床医院泌尿外科,南充 637000
  2.重庆医科大学附属第二医院泌尿外科,重庆 400010
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003306
  CLC： R737
- Received：31 May 2023，
  
  Revised：2023-07-08，
  
  Accepted：16 July 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
谭小军,周玉,赵攀,等.泛素结合酶2C通过Wnt/β-catenin信号通路促进肾恶性横纹肌样瘤的恶性进展[J].重庆医科大学学报,2023,48(8):958-964.

Tan Xiaojun,Zhou Yu,Zhao Pan,et al.Ubiquitin-conjugating enzyme 2C promotes malignant progression of malignant rhabdoid tumor of the kidney via the Wnt/β-catenin signaling pathway[J].Journal of Chongqing Medical University,2023,48(8):958-964.
谭小军,周玉,赵攀,等.泛素结合酶2C通过Wnt/β-catenin信号通路促进肾恶性横纹肌样瘤的恶性进展[J].重庆医科大学学报,2023,48(8):958-964. DOI： 10.13406/j.cnki.cyxb.003306.

Tan Xiaojun,Zhou Yu,Zhao Pan,et al.Ubiquitin-conjugating enzyme 2C promotes malignant progression of malignant rhabdoid tumor of the kidney via the Wnt/β-catenin signaling pathway[J].Journal of Chongqing Medical University,2023,48(8):958-964. DOI： 10.13406/j.cnki.cyxb.003306.

摘要

目的

探讨泛素结合酶2C（ubiquitin-conjugating enzyme 2 C，UBE2C）对肾恶性横纹肌样瘤（malignant rhabdoid tumor of the kidney，MRTK）的影响及作用机制。

方法

采用蛋白免疫印迹（Western blot，WB）以及免疫荧光法在收集的MRTK临床标本以及细胞系G401细胞中验证UBE2C的表达情况。从TARGET数据库下载MRTK的基因表达数据进行验证，Kaplan-Meier法（KM法）评估UBE2C与预后的关系。采用小干扰RNA（small interfering RNA，siRNA）抑制UBE2C在G401细胞中的表达。通过CCK-8检测转染后G401细胞增殖情况，流式细胞术检测细胞凋亡能力，划痕实验和Transwell实验分别检测细胞迁移和侵袭能力的改变。采用基因集富集分析（Gene Set Enrichment Analysis，GSEA）探索UBE2C调控的相关通路，并通过WB验证通路蛋白的表达。

结果

在MRTK临床标本中，UBE2C表达量是癌旁对照组的（3.189±1.900）倍（

=0.033）。G401细胞系中UBE2C表达量是HEK293细胞的（2.092±0.231）倍（

=0.000），KM生存分析显示，高表达UBE2C的患者预后更差（

=0.019），并且UBE2C在4期患者（680.9±167.7）中高于早期患者（560.5±166.9），差异有统计学意义（

=0.021）。采用siRNA成功将UBE2C的表达敲低至（0.446±0.058）倍（

=0.000），并且发现敲低UBE2C抑制了G401细胞增殖、侵袭、迁移以及促进了细胞凋亡（

=0.000）。GSEA富集分析发现UBE2C与Wnt/β-catenin信号通路相关（

=0.000），敲低UBE2C可以抑制Wnt/β-catenin信号通路及上皮间质转换（epithelial-mesenchymal transition，EMT）（

=0.000）。

结论

UBE2C在MRTK中高表达与不良预后相关，参与调控Wnt/β-catenin信号通路，抑制UBE2C可以抑制MRTK的增殖、迁移、侵袭，EMT，促进其凋亡。

Abstract

Objective

To investigate the influence of ubiquitin-conjugating enzyme 2C（UBE2C） on malignant rhabdoid tumor of the kidney（MRTK） and its mechanism of action.

Methods

Western blot and immunofluorescence assay were used to verify the expression of UBE2C in MRTK clinical specimens and G401 cells. Gene expression data of MRTK were downloaded from the TARGET database for validation，and the Kaplan-Meier method was used to assess the association between UBE2C and prognosis. Small interfering RNA（siRNA） was used to inhibit the expression of UBE2C in G401 cells. CCK-8 assay was used to observe the proliferation of G401 cells after transfection，flow cytometry was used to observe cell apoptosis，and scratch assay and Transwell assay were used to observe the changes in cell migration and invasion abilities. Gene Set Enrichment Analysis（GSEA） was used to explore the pathways regulated by UBE2C，and Western blot was used to verify the expression of pathway proteins.

Results

The expression of UBE2C in MRTK clinical specimens was 3.189±1.900 times that in adjacent control samples（

=0.033）. The expression of UBE2C in G401 cells was 2.092±0.231 times that in HEK293 cells（

=0.000）. The Kaplan-Meier survival analysis showed that the patients with high UBE2C expression tended to have a worse prognosis（

=0.019），and the patients with stage 4 MRTK had a significantly higher expression of UBE2C than the patients in the early stage（680.9±167.7 vs. 560.5±166.9，

=0.021）. Our research group successfully knocked down the expression of UBE2C to 0.446±0.058 folds（

=0.000） by using siRNA，and it was found that UBE2C knockdown inhibited the proliferation，invasion，and migration of G401 cells and promoted the apoptosis of G401 cells（

=0.000）. GSEA enrichment analysis revealed that UBE2C was associated with the Wnt/β-catenin signaling pathway（

=0.000），and UBE2C knockdown inhibited the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition（EMT）（

=0.000）.

Conclusion

The high expression of UBE2C in MRTK is associated with poor prognosis and is involved in the regulation of the Wnt/β-catenin signaling pathway，and inhibition of UBE2C can inhibit proliferation，migration，invasion，and EMT and promote apoptosis in MRTK.

关键词

Keywords

references

van den Heuvel-Eibrink MM ， van Tinteren H ， Rehorst H ， et al . Malignant rhabdoid tumours of the kidney（MRTKs），registered on recent SIOP protocols from 1993 to 2005：a report of the SIOP renal tumour study group [J ] . Pediatr Blood Cancer ， 2011 ， 56 （ 5 ）： 733 - 737 .

成海燕，杨深，蔡思雨，等 . 35例儿童肾恶性横纹肌样瘤临床及预后特征 [J ] . 中国小儿血液与肿瘤杂志， 2018 ， 23 （ 3 ）： 118 - 123 .

Cheng HY ， Yang S ， Cai SY ， et al . Clinical and prognostic characteristics of 35 cases of Malignant rhabdoid tumours of the kidney [J ] . Chinese Journal of Pediatric Hematology and Oncology ， 2018 ， 23 （ 3 ）： 118 - 123 .

Reinhard H ， Reinert J ， Beier R ， et al . Rhabdoid tumors in children：prognostic factors in 70 patients diagnosed in Germany [J ] . Oncology Reports ， 2008 ， 19 （ 3 ）： 819 - 823 .

Kim KH ， Roberts CW . Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth [J ] . Cancer Genetics ， 2014 ， 207 （ 9 ）： 365 - 372 .

Moe KC ， Maxwell JN ， Wang J ， et al . The SWI/SNF ATPase BRG1 facilitates multiple pro-tumorigenic gene expression programs in SMARCB1-deficient cancer cells [J ] . Oncogenesis ， 2022 ， 11 （ 1 ）： 30 .

Panwalkar P ， Pratt D ， Chung C ， et al . SWI/SNF complex heterogeneity is related to polyphenotypic differentiation，prognosis，and immune response in rhabdoid tumors [J ] . Neuro-oncology ， 2020 ， 22 （ 6 ）： 785 - 796 .

Hong AL ， Tseng YY ， Wala JA ， et al . Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition [J ] . eLife ， 2019 ， 8 ： e44161 .

Derenzini E ， Mondello P ， Erazo T ， et al . BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors [J ] . Cell Reports ， 2018 ， 24 （ 8 ）： 2155 - 2166 .

Vokshi BH ， Davidson G ， Tawanaie Pour Sedehi N ， et al . SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance [J ] . Nature Communications ， 2023 ， 14 （ 1 ）： 3034 .

Xie C ， Powell C ， Yao M ， et al . Ubiquitin-conjugating enzyme E2C：a potential cancer biomarker [J ] . The International Journal of Biochemistry & Cell Biology ， 2014 ， 47 ： 113 - 117 .

Liu Y ， Zhao R ， Chi S ， et al . UBE2C Is Upregulated by Estrogen and Promotes Epithelial-Mesenchymal Transition via p53 in Endometrial Cancer [J ] . Mol Cancer Res ， 2020 ， 18 （ 2 ）： 204 - 215 .

Zhang S ， You X ， Zheng Y ， et al . The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells [J ] . The Journal of Clinical Investigation ， 2023 ， 133 （ 4 ）： e162434 .

Kariri Y ， Toss MS ， Alsaleem M ， et al . Ubiquitin-conjugating enzyme 2C（UBE2C） is a poor prognostic biomarker in invasive breast cancer [J ] . Breast Cancer Research and Treatment ， 2022 ， 192 （ 3 ）： 529 - 539 .

Hutzen B ， Paudel SN ， Naeimi Kararoudi M ， et al . Immunotherapies for pediatric cancer：current landscape and future perspectives [J ] . Cancer Metastasis Reviews ， 2019 ， 38 （ 4 ）： 573 - 594 .

Geoerger B ， Bourdeaut F ， DuBois SG ， et al . A Phase I Study of the CDK4/6 Inhibitor Ribociclib（LEE011） in Pediatric Patients with Malignant Rhabdoid Tumors，Neuroblastoma，and Other Solid Tumors [J ] . Clin Cancer Res ， 2017 ， 23 （ 10 ）： 2433 - 2441 .

Mardinian K ， Adashek JJ ， Botta GP ， et al . SMARCA4：Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy [J ] . Molecular Cancer Therapeutics ， 2021 ， 20 （ 12 ）： 2341 - 2351 .

Nemes K ， Frühwald MC . Emerging therapeutic targets for the treatment of malignant rhabdoid tumors [J ] . Expert Opinion on Therapeutic Targets ， 2018 ， 22 （ 4 ）： 365 - 379 .

Wang R ， Song Y ， Liu X ， et al . UBE2C induces EMT through Wnt/β‑catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A [J ] . International Journal of Oncology ， 2017 ， 50 （ 4 ）： 1116 - 1126 .

Xu J ， Chen M ， Hu M ， et al . Claudin 19 inhibits the malignant potential of breast cancer cells by modulating extracellular matrix-associated UBE2C/Wnt signaling [J ] . American Journal of Cancer Research ， 2022 ， 12 （ 12 ）： 5552 - 5563 .

Cao JZ ， Nie G ， Hu H ， et al . UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation [J ] . Journal of Gastrointestinal Oncology ， 2022 ， 13 （ 3 ）： 1444 - 1453 .

Chiang AJ ， Li CJ ， Tsui KH ， et al . UBE2C drives human cervical cancer progression and is positively modulated by mTOR [J ] . Biomolecules ， 2020 ， 11 （ 1 ）： 37 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Adenosine deaminase acting on RNA 1 p150 and p110 are involved in the proliferation，migration，and invasion of liver cancer cells

Research advances in the Wnt/β-catenin signaling pathway in neuronal degeneration in Alzheimer’s Disease

Effect of TNF-α on adipogenesis of SD rat bone marrow mesenchymal stem cells and the related molecular mechanism

Effect of Wnt/?茁 -catenin signaling pathway on the repair of orthodontic root resorption

Inhibition of B cell lymphoma 6 member B on proliferation and migration of colorectal carcinoma cell line HCT116 and study of its possible mechanism

Related Author

Tu Zeng

Gong Xue

Cui Yihong

Jian Wenwen

Liu Jing

Fu Pengyu

Chen Yilun

Chang Kaixuan

Related Institution

Department of Pathogen Biology，School of Basic Medical Sciences，Chongqing Medical University

School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine

Department of Gastroenterology,The First Affiliated Hospital of Chongqing Medical University

Center of Digestion,Affiliated University Town Hospital of Chongqing Medical University

Department of Orthodontics，Stomatology Hospital of Chongqing Medical University，Key Laboratory of Chongqing City for Oral Diseases and Biomedical Sciences

⁰